ClinicalTrials.gg
CompletedNCT04371380Updated Apr 22, 2024Results posted

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

A Phase 1 interventional study of Cabotegravir Tablets and Rilpivirine Tablets in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
33rd of 36
15 · median 200
Started
2020
with 5 others
Phase 1
10 of 36
none open now
Registered
19th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 33rd largest by enrollment, is one of 6 that started in 2020, is one of 10 in phase 1, and was the 19th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This is a phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir and rilpivirine in plasma following the administration of a single 600 milligram (mg) and a 900 mg intramuscular (IM) injection respectively, to separate vastus lateralis muscles on each leg. Cabotegravir is an integrase inhibitor being developed in combination with rilpivirine, a non-nucleoside reverse transcriptase inhibitor, for the treatment of human immunodeficiency virus (HIV). The objective is to evaluate pharmacokinetics, tolerability, and safety of cabotegravir long acting plus rilpivirine long acting administered concomitantly as two separate IM injections in the vastus lateralis muscle of adult healthy participants. The screening phase will be of 30 days, oral lead-in (OLI) phase of 28 days, there will be washout period of 10-14 days, followed by an injection phase and follow-up period will be up to 52-weeks. Approximately 15 adult healthy participants will be enrolled.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • cabotegravir
  • rilpivirine
  • HIV
  • Pharmacokinetics
  • intramuscular injection
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 50 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range may be included only if the investigator in consultation with the medical monitor agree and document that the finding is unlikely to introduce additional risk and will not interfere with the study procedures. A single repeat of a procedure or laboratory parameter is allowed to determine eligibility.
  • Participants who are negative on two consecutive tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19), performed at Screening and on Day -1 of admission to the Phase I unit, using an approved molecular test (polymerase chain reaction or antigen test).
  • Body weight >=40 kilogram (Kg) and (BMI) within the range 18 to 35 kg per square meter (inclusive).
  • Male or female. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants: Male participants are eligible to participate if they agree to the following during the intervention period and for at least 52 weeks after the last dose of study intervention; refrain from donating sperm plus either be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception/barrier as detailed; agree to use a male condom when having sexual intercourse with a woman of who is not currently pregnant, agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person. Female participants: a female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies; is not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of less than 1 percent (%,) during the intervention period and for atleast 52 weeks after the last dose of study intervention; the investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention; a WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 30 days of the first dose of study intervention, if a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive; the investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Signs and symptoms which in the opinion of the investigator are suggestive of COVID-19 (example; fever, cough etc) within 14 days of inpatient admission
  • Contact with known COVID-19 positive person/s in the 14 days prior to inpatient admission
  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Abnormal blood pressure as determined by the investigator.
  • (ALT) greater than 1.5 times (ULN).
  • greater than 1.5 times ULN (isolated bilirubin greater than 1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • History of ongoing or seizure disorder within the previous 2 years, including participants who have required treatment for seizures within this time period. A prior history of seizure, with a seizure free period of at least 2 years, off anti-epileptics, may be considered for enrollment if the investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the medical monitor prior to enrollment.
  • corrected for heart rate (QTc) greater than 450 millisecond for male participants and greater than 470 milliseconds for female participants
  • A participant, who has an underlying skin disease or disorder (i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria).
  • A participant, who is considered to have insufficient musculature to allow safe administration of cabotegravir or rilpivirine in the opinion of the investigator will be excluded.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication to the completion of the follow-up visit unless in the opinion of the Investigator and ViiV medical monitor the medication will not interfere with the study procedures or compromise participant safety.
  • Participation in the study would result in loss of blood or blood products in excess of 500 mililiter within 56 days.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Participant has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Presence of the Hepatitis B core antibody (HBcAb) should also lead to exclusion from the study even if HBsAg is negative.
  • Positive pre-study drug/alcohol screen
  • Positive (HIV) antibody test
  • Regular use of known drugs of abuse
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 units for males or >7 units for females. One unit is equivalent to 8 grams of alcohol: a half-pint (\~240 milliliter) of beer, 1 glass (125 milliliter) of wine or 1 (25 milliliter) measure of spirits.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6 months prior to screening.
  • Participant, who has a tattoo or other dermatological condition overlying the thigh region which may interfere with interpretation of injection site reactions.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    OLI phase followed by Injection phase

    Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.

    Drug: Cabotegravir Tablets · Drug: Rilpivirine Tablets · Drug: Cabotegravir extended release suspension for injection (long-acting) · Drug: Rilpivirine extended release suspension for injection (long-acting)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  2. Cmax of Rilpivirine (RPV) Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  3. Time of Cmax (Tmax) of CAB Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  4. Tmax of RPV Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  5. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  6. AUC(0-t) of RPV Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  7. AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  8. AUC(0-infinity) of RPV Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  9. Apparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  10. t1/2 of RPV Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  11. Geometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of CAB.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

  12. Geometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection

    Blood samples were collected at indicated time points for PK analysis of RPV.

    Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52

Secondary outcomes

  1. Number of Participants With Liver Related Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 56 weeks

  2. Number of Participants With Liver Related Abnormalities

    Blood samples were collected to assess abnormalities related to liver.

    Time frame: Up to 56 weeks

07

Results

Posted Apr 22, 2024

Participant flow

Oral Lead-in Phase (Up to Day 28)
Participant flow — Oral Lead-in Phase (Up to Day 28)
MilestoneOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Started1500
Completed1400
Not completed100
Withdrew: Physician decision100
Injection Phase (IP)-Day 1[IP] to Week 4
Participant flow — Injection Phase (IP)-Day 1[IP] to Week 4
MilestoneOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Started0140
Completed0140
Not completed000
Follow-up Phase (Week 4 to Week 52)
Participant flow — Follow-up Phase (Week 4 to Week 52)
MilestoneOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Started0014
Completed0014
Not completed000

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection
Microgram per milliliter (ug/mL)IM CAB 600 mg
Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection3.38 ± 66
PrimaryCmax of Rilpivirine (RPV) Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax of Rilpivirine (RPV) Following Single IM Injection
nanogram per milliliter (ng/mL)IM RPV 900mg
Cmax of Rilpivirine (RPV) Following Single IM Injection93.5 ± 37.7
PrimaryTime of Cmax (Tmax) of CAB Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Median · Hour
Time of Cmax (Tmax) of CAB Following Single IM Injection
HourIM CAB 600 mg
Time of Cmax (Tmax) of CAB Following Single IM Injection167 (166 to 1317)
PrimaryTmax of RPV Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Median · Hour
Tmax of RPV Following Single IM Injection
HourIM RPV 900mg
Tmax of RPV Following Single IM Injection131 (70.1 to 647)
PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Hour*microgram per milliliter (h*ug/mL)
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection
Hour*microgram per milliliter (h*ug/mL)IM CAB 600 mg
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection3612 ± 23
PrimaryAUC(0-t) of RPV Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) of RPV Following Single IM Injection
h*ng/mLIM RPV 900mg
AUC(0-t) of RPV Following Single IM Injection143891 ± 33
PrimaryAUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · h*ug/mL
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection
h*ug/mLIM CAB 600 mg
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection3948 ± 21.5
PrimaryAUC(0-infinity) of RPV Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) of RPV Following Single IM Injection
h*ng/mLIM RPV 900mg
AUC(0-infinity) of RPV Following Single IM Injection171953 ± 31.1
PrimaryApparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Days
Apparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection
DaysIM CAB 600 mg
Apparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection21.4 ± 79.3
Primaryt1/2 of RPV Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Days
t1/2 of RPV Following Single IM Injection
DaysIM RPV 900mg
t1/2 of RPV Following Single IM Injection137 ± 26.6
PrimaryGeometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of CAB.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Per hour (/h)
Geometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection
Per hour (/h)IM CAB 600 mg
Geometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection0.00135 ± 79.3
PrimaryGeometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection

Blood samples were collected at indicated time points for PK analysis of RPV.

Time frame:
Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Reported as:
Geometric mean · Per hour (/h)
Geometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection
Per hour (/h)IM RPV 900mg
Geometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection0.000211 ± 26.6
SecondaryNumber of Participants With Liver Related Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Liver Related Adverse Events (AEs)
ParticipantsOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Number of Participants With Liver Related Adverse Events (AEs)000
SecondaryNumber of Participants With Liver Related Abnormalities

Blood samples were collected to assess abnormalities related to liver.

Time frame:
Up to 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Liver Related Abnormalities
ParticipantsOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Number of Participants With Liver Related Abnormalities000

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 56 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg0/15 (0%)0/15 (0%)3/15 (20%)
Injection Phase - CAB 600mg + RPV 900mg0/14 (0%)0/14 (0%)14/14 (100%)
Follow-up Phase - CAB 600mg + RPV 900mg0/14 (0%)0/14 (0%)2/14 (14.3%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mgInjection Phase - CAB 600mg + RPV 900mgFollow-up Phase - CAB 600mg + RPV 900mg
Injection site painGeneral disorders0/1514/140/14
Injection site erythemaGeneral disorders0/158/140/14
Injection site indurationGeneral disorders0/157/140/14
Injection site swellingGeneral disorders0/156/140/14
Injection site bruisingGeneral disorders0/154/140/14
ChillsGeneral disorders0/153/140/14
Injection site warmthGeneral disorders0/153/140/14
Injection site pruritusGeneral disorders0/152/140/14
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/152/140/14
BlepharitisEye disorders0/151/140/14

Baseline characteristics

All enrolled population included participants who signed the informed consent form and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(YEARS)All Enrolled Participants
Mean34.3 ± 7.72
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Participants
Female6
Male9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Enrolled Participants
Asian1
Black or African American7
White7
08

Study locations

1 site
  • GSK Investigational Site
    Glendale, California 91206, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2021, 15 months.

Results were first posted in Apr 2024, 2 years 3 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2020
First posted
May 1, 2020
StartActual
Sep 16, 2020
Primary completionActual
Dec 26, 2021
CompletionActual
Dec 26, 2021
Results first posted
Apr 22, 2024
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04371380
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
May 1, 2020
Start date
Sep 16, 2020
Primary completion
Dec 26, 2021
Completion
Dec 26, 2021
Results posted
Apr 22, 2024
Last update
Apr 22, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabotegravir · Rilpivirine

Start the discussion